Evidence map›Paper›PMID 38699357›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.

Yuta Katsumi, Inola A Howe, Ryan Eckbo, Bonnie Wong, Megan Quimby, Daisy Hochberg, Scott M McGinnis, Deepti Putcha, David A Wolk, Alexandra Touroutoglou and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Yuta KatsumiFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-0413-747X
Inola A HoweFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ryan EckboFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Bonnie WongFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Megan QuimbyFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Daisy HochbergFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Scott M McGinnisFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Deepti PutchaFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
David A WolkDepartment of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Alexandra TouroutoglouFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Bradford C DickersonFrontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-5958-3445

Funding

THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HEDDEN, JULIUS C · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MATTHEW P FROSCH · 2019 to 2026
$36.5M
Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Project 4P41EB015896 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2012 to 2018
$9.8M
Imaging tau, amyloid, and neurodegeneration in PPAR01DC014296 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, JOHNSON, KEITH A. · 2016 to 2020
$4.3M
Robust detection of atrophy over short intervals in AD and FTLDR01AG081249 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI BRADFORD C DICKERSON · 2023 to 2026
$3.3M
Toward Personalized Prognosis and Outcomes in Primary Progressive AphasiaRF1NS131395 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C · 2023 to 2023
$2.5M
A Storage Area Network for Structural and Functional Image AnalysisS10RR023401 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI FISCHL, BRUCE · 2009 to 2009
$2.0M
SILICON GRAPHICS PRISM EXTREME 128P/1TBS10RR023043 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI SORENSEN, ALMA GREGORY · 2006 to 2006
$1.5M
TMS in Primary Progressive Aphasia: Modulation of Brain Networks and LanguageK23DC016912 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI TOUROUTOGLOU, ALEXANDRA · 2019 to 2023
$871k
A Siemens MAGNETOTOM Trio 3 Tesla MRI SystemS10RR021110 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI ROSEN, BRUCE R · 2006 to 2006
$500k
Neuromodulation of brain network function in preclinical and prodromal Alzheimer's DiseaseR21AG080588 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI DICKERSON, BRADFORD C, TOUROUTOGLOU, ALEXANDRA · 2023 to 2024
$462k
NCRR NIH HHS S10 RR021110NCRR NIH HHS S10 RR023043NCRR NIH HHS S10 RR023401NIA NIH HHS K01 AG084820NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG072979NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG081249NIA NIH HHS R21 AG080588NIBIB NIH HHS P41 EB015896NIDCD NIH HHS K23 DC016912NIDCD NIH HHS R01 DC014296NINDS NIH HHS RF1 NS131395
6 · The paper itself

Abstract

Identifying individuals with early stage Alzheimer's disease (AD) at greater risk of steeper clinical decline would allow professionals and loved ones to make better-informed medical, support, and life planning decisions. Despite accumulating evidence on the clinical prognostic value of tau PET in typical late-onset amnestic AD, its utility in predicting clinical decline in individuals with atypical forms of AD remains unclear. In this study, we examined the relationship between baseline tau PET signal and the rate of subsequent clinical decline in a sample of 48 A

Indexed as

cerebral cortexearly-onset Alzheimer’s diseaseneurodegenerationneuroimagingposition emission tomographytau pathology

Identifiers

PMID38699357
PMCPMC11065041

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.